Last reviewed · How we verify
topical Timolol maleate 0.5% eye drops
Timolol maleate is a non-selective beta-adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye.
Timolol maleate is a non-selective beta-adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | topical Timolol maleate 0.5% eye drops |
|---|---|
| Sponsor | Ain Shams University |
| Drug class | Beta-adrenergic antagonist (non-selective) |
| Target | Beta-1 and beta-2 adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Timolol blocks beta-1 and beta-2 adrenergic receptors on the ciliary body epithelium, which reduces the rate of aqueous humor secretion. This leads to a decrease in intraocular pressure, making it effective for treating glaucoma and ocular hypertension. The 0.5% topical formulation is applied directly to the eye for local therapeutic effect.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Ocular irritation or discomfort
- Blurred vision
- Conjunctival hyperemia
- Systemic beta-blockade effects (bradycardia, bronchospasm in susceptible patients)
Key clinical trials
- Efficacy of 0.5% Topical Timolol Eye Drops in the Treatment of Post-Inflammatory Erythema Following Acne Vulgaris (EARLY_PHASE1)
- Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas (PHASE4)
- Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing (PHASE2)
- Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension (PHASE2)
- Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia (PHASE3)
- Efficacy and Safety of Timolol for TKI Induced Paronychia (PHASE3)
- Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension (PHASE2)
- A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- topical Timolol maleate 0.5% eye drops CI brief — competitive landscape report
- topical Timolol maleate 0.5% eye drops updates RSS · CI watch RSS
- Ain Shams University portfolio CI